A Randomized Phase III trial of Paclitaxel plus Cisplatin versus Paclitaxel plus Carboplatin in Stage IVB, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)

Phase 3

• Conditions: uterine cervical neoplasms

• Registration Number: JPRN-C000000335
• Lead Sponsor: Japan Clinical Oncology Group(JCOG)

Brief Summary

See the datails via "URL releasing results" above. Also the details can be seen in the JCOG website: http://www.jcog.jp/en/trials/index.html

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-02-21
• Study Completion: 2011-11-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: Female
• Target Recruitment: 250

Inclusion Criteria

Not provided

Exclusion Criteria

1) patients who have some neurologically functional disorder 2) symptomatic CNS metastasis 3) hypersensitive to alcohol 4) active infection 5) HBs antigen positive 6) uncontrollable hypertension 7) history of myocardiac infarction within six months 8) unstable angina 9) uncontrollable diabetes 10) Patients with a concomitant or prior invasive malignancy (except intramucosal malignancy which are curable with local therapy) who have had any evidence of the disease within the last 5 years 11) women during pregnancy or breast-feeding 12) patients with psychiatric liiness 13) patients who have been treated with the systemic steroids medication

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
overall survival

Secondary Outcome Measures

Name	Time	Method
progression-free survival, response rate, adverse events, severe adverse events, proportion of periods of non-hospitalization to those of the planned treatment